| Anti-inflammatory drugs | P value | n | |
---|---|---|---|---|
No (n = 63) | Yes (n = 123) | |||
Corticosteroid monotherapy | 0 (0.0) | 39 (31.7) | < 0.001 | 186 |
Combined with immunosuppressants | 0 (0.0) | 84 (68.3) | < 0.001 | 186 |
Cyclosporine A | 0 (0.0) | 56 (45.5) | ||
Tacrolimus | 0 (0.0) | 5 (4.1) | ||
Cyclophosphamide | 0 (0.0) | 13 (10.6) | ||
Azathioprine | 0 (0.0) | 10 (8.1) | ||
Anti-fibrotic drugs* | 20 (31.7) | 30 (24.4) | 0.370 | 186 |
 Pirfenidone | 14 (22.2) | 23 (18.7) | ||
 Nintedanib | 5 (7.9) | 7 (5.7) | ||
One-year changes | ||||
 ΔLDH (IU/L) | − 15.1 ± 84.7 | − 16.8 ± 192.3 | 0.934 | 168 |
 ΔKL-6 (U/mL) | − 347 ± 1234 | − 602 ± 1691 | 0.270 | 169 |
 ΔSP-D (ng/mL) | 16.4 ± 121.1 | − 168.5 ± 558.1 | 0.004 | 131 |
 ΔFVC % predicted (%) | − 2.9 ± 10.9 | 3.1 ± 19.7 | 0.016 | 156 |
 ΔDLCO % predicted (%) | − 1.9 ± 25.6 | 5.5 ± 20.8 | 0.113 | 132 |
One-year outcomes | ||||
 Improvement** | 7 (14.9) | 41 (37.6) | 0.015 | 156 |
 Stable | 26 (55.3) | 44 (40.4) | ||
 Worsening*** | 14 (29.8) | 24 (22.0) | ||
Death during observation period | 11 (17.5) | 31 (25.2) | 0.270 | 186 |